883987-72-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-5-nitrobenzoic acid Methyl ester serves as a crucial intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medications. Its unique chemical structure and properties allow for the creation of organic compounds with diverse functionalities, which are essential in medicinal chemistry.
Used in Agrochemical Synthesis:
In the agrochemical sector, 3-Fluoro-5-nitrobenzoic acid Methyl ester is utilized as an intermediate for the production of various agrochemicals. Its ability to be manipulated in chemical reactions facilitates the synthesis of compounds that can be used in the development of pesticides, herbicides, and other agricultural products to improve crop yields and protect against pests.
Used in Organic Chemistry Research:
3-Fluoro-5-nitrobenzoic acid Methyl ester is also valuable in organic chemistry research, where it can be employed to explore new reaction pathways, develop novel synthetic methods, and understand the reactivity of fluorinated and nitro-containing compounds. Its presence in chemical reactions can provide insights into structure-activity relationships and the influence of functional groups on molecular properties.

Upstream product

• 14027-75-9 3-nitro-5-fluorobenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 

Downstream Products

• 1448347-96-3 2-(3-amino-5-fluorophenyl)propan-2-ol 
• 884497-46-5 methyl 3-amino-5-fluorobenzoate 
• 1448347-94-1 Methyl 3-(dibenzylamino)-5-fluorobenzoate 
• 1448347-95-2 2-(3-(dibenzylamino)-5-fluorophenyl)propan-2-ol 
• 914636-93-4 3-fluoro-5-iodobenzaldehyde 
• 883987-74-4 3-fluoro-5-nitrobenzyl alcohol 

Relevant academic research and scientific papers

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)

The mitogen-activated protein kinase (MAP) kinase 4 (MKK4) was found to be a major regulator of liver regeneration and could be a valuable drug target addressing liver related diseases by restoring its intrinsic regenerative capacity. We report on the synthesis and optimization of novel MKK4 inhibitors following a target-hopping strategy from the FDA-approved BRAFV600E inhibitor PLX4032 (8). Applying an iterative multi-parameter optimization process we carved out essential structural features yielding in compounds with a low nanomolar affinity for MKK4 and excellent selectivity profiles against the main off-targets MKK7 and JNK1, which, upon relevant inhibition, would totally abrogate the pro-regenerative effect of MKK4 inhibition, as well as against the off-targets MAP4K5, ZAK and BRAF with selectivity factors ranging from 40 to 430 for our best-balanced compounds 70 and 73.

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.